Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 24
Filtrer
1.
Toxicol Res (Camb) ; 13(1): tfae004, 2024 Feb.
Article de Anglais | MEDLINE | ID: mdl-38274036

RÉSUMÉ

The safety of a rhamnogalacturonan-I-enriched pectin extract (G3P-01) from pumpkin (Cucurbita moschata var. Dickinson) was evaluated for use as an ingredient in food and dietary supplements. G3P-01 was tested in a battery of genetic toxicity studies including reverse mutagenicity and in vitro micronucleus assay. In addition, Sprague-Dawley rats were randomized and orally dosed with G3P-01 incorporated in animal diet at concentrations of 0, 9000, 18,000, and 36,000 ppm daily for 13-weeks (n=10/sex/group) in line with OECD guidelines (TG 408). The results of the in vitro bacterial reverse mutation assay and micronucleus assay in TK6 cells demonstrated a lack of genotoxicity. The 13-week oral toxicity study in Sprague-Dawley rats demonstrated that the test article, G3P-01 was well tolerated; there were no mortalities and no adverse effects on clinical, gross pathology, hematology, blood chemistry, and histological evaluation of the essential organs of the animals. The present study demonstrates that G3P-01 is non-genotoxic and is safe when ingested in diet at concentrations up to 36, 000 ppm. The subchronic no-observed-adverse-effect level (NOAEL) for G3P-01 was concluded to be 36,000 ppm, equivalent to 1,899 and 2,361 mg/kg/day for male and female rats respectively.

2.
Toxicol Res (Camb) ; 11(6): 1003-1017, 2022 Dec.
Article de Anglais | MEDLINE | ID: mdl-36569482

RÉSUMÉ

Filamentous fungus biomass is a protein-rich food, which can serve as an alternative to animal, plant, and legume protein sources. Neurospora crassa is a filamentous fungus that typically grows in tropical and sub-tropical regions. Traditionally, N. crassa has served as a model eukaryotic organism due to its ease of growth and propagation and suitability for genetic manipulation. However, filamentous fungi, such as Neurospora, have also been consumed or used to produce fermented foods for centuries and have been developed into protein-rich biomass ingredients to be used in conventional foods and meat substitutes. A panel of toxicological tests including genotoxic, acute, and subchronic studies were conducted on dried N. crassa biomass to support its safe use in food. The dried N. crassa biomass was found to be not genotoxic in a bacterial reverse mutation (Ames) assay, an in vitro chromosomal aberration test, and an in vivo micronucleus test. In the acute and subchronic toxicity studies, rats were orally gavaged with N. crassa biomass at concentrations of 0, 1,000, 2,500, and 5,000 mg/kg body weight/day for 14 and 90 days, respectively. At the conclusion of the studies, there were no test article-related toxicity results observed in clinical observations, body weight, food consumption, ophthalmology, hematology, clinical chemistry, coagulation, thyroid hormone, urinalysis, and macroscopic and microscopic findings. The no-observed-adverse-effect level for the dried N. crassa biomass ingredient was determined to be 5,000 mg/kg body weight/day, the highest dose tested.

3.
Food Chem Toxicol ; 168: 113342, 2022 Oct.
Article de Anglais | MEDLINE | ID: mdl-35963473

RÉSUMÉ

Cultivation of filamentous fungi to produce sustainable, nutrient rich meat replacements has recently attracted significant commercial and research interest. Here, we report evidence for the safety and nutritional value of Neurospora crassa mycoprotein, a whole mycelium food ingredient produced by fermentation and minimal downstream processing. N. crassa has a long history of human use in fermented foods and in molecular biology research. A survey of studies that used N. crassa in animal feed revealed no adverse effects to the health of the animals. Furthermore, a review of the literature found no reports of confirmed allergenicity or toxicity in humans involving N. crassa. Genomic toxigenicity analysis and in vitro testing did not identify any toxins in N. crassa mycoprotein. Two independent genomic allergenicity studies did not identify proteins that would be considered a particular risk for allergenic potential. Furthermore, nutritional analysis demonstrated that N. crassa mycoprotein is a good source of complete protein and is rich in fiber, potassium, and iron. Taken together, the presented data and the history of human use without evidence of human or animal harm indicate that foods containing N. crassa can generally be regarded as safe.


Sujet(s)
Ingrédients alimentaires , Neurospora crassa , Animaux , Humains , Fer/métabolisme , Viande , Neurospora crassa/génétique , Neurospora crassa/métabolisme , Potassium/métabolisme
4.
PLoS One ; 16(6): e0253992, 2021.
Article de Anglais | MEDLINE | ID: mdl-34181690

RÉSUMÉ

[This corrects the article DOI: 10.1371/journal.pone.0040702.].

5.
Case Rep Infect Dis ; 2021: 8865339, 2021.
Article de Anglais | MEDLINE | ID: mdl-33777466

RÉSUMÉ

We describe a case of gonococcal spontaneous bacterial peritonitis (SBP) in a 48-year-old sexually active female with alcoholic cirrhosis and chronic hepatitis B. She was admitted with fever, abdominal pain and distension without dysuria, dyspareunia, or vaginal discharge. On exam, she was icteric with features of sepsis and tense ascites. She underwent paracentesis. The ascitic fluid analysis revealed a neutrophil count of 1,050/µL, and culture grew Neisseria gonorrhoeae. Pelvic examination findings were negative for pelvic inflammatory disease; however, an endocervical swab was positive for N. gonorrhoeae by PCR. She was diagnosed with spontaneous bacterial peritonitis secondary to N. gonorrhoeae and was successfully treated with a seven-day course of IV ceftriaxone. N. gonorrhoeae spontaneous bacterial peritonitis is an extremely rare entity reported only twice despite the high prevalence of gonorrhoeae in the general population. We hypothesize that gonococcal SBP may be frequently undiagnosed since it responds to empiric antibiotics used to treat SBP. It is important for the clinician to be aware of gonococcus as a rare but potential pathogen in SBP. Future studies are needed to determine if routine gonococcal screening in SBP cases would be of clinical utility.

6.
J Appl Toxicol ; 40(10): 1342-1352, 2020 10.
Article de Anglais | MEDLINE | ID: mdl-32346895

RÉSUMÉ

Pantoea agglomerans is a Gram-negative bacterium that is ubiquitous in the environment, colonizing animals, humans, and numerous plants, including cotton and wheat. A lipopolysaccharide-containing fermented wheat flour extract from P. agglomerans (Somacy-FP100) is proposed for use as a food ingredient for individuals seeking foods for healthy aging. Previously published genotoxicity studies with Somacy-FP100 reported its lack of genotoxicity in vitro, but a subchronic toxicity study has not yet been performed. Therefore, to demonstrate the safety of Somacy-FP100 for use as a food ingredient, a 90-day oral (gavage) toxicity study in rats was conducted. Male and female Han Wistar rats were administered vehicle (control) or Somacy-FP100 at 500, 1500, or 4500 mg/kg body weight/day at a dose volume of 10 mL/kg body weight, for at least 90 days. No test article-related adverse clinical signs or effects on body weight, food consumption, or clinical pathology were observed, and there were no macroscopic or microscopic findings related to the test article. Therefore, 4500 mg/kg body weight/day (the highest dose tested and highest feasible dose) was established as the no-observed-adverse-effect level. This absence of subchronic toxicity, in addition to the previously reported lack of genotoxicity, demonstrates the safety of Somacy-FP100 for use as a food ingredient.


Sujet(s)
Grains comestibles/parasitologie , Infections à Enterobacteriaceae/étiologie , Farine/toxicité , Lipopolysaccharides/toxicité , Pantoea/composition chimique , Extraits de plantes/toxicité , Triticum/parasitologie
7.
Regul Toxicol Pharmacol ; 110: 104523, 2020 Feb.
Article de Anglais | MEDLINE | ID: mdl-31726192

RÉSUMÉ

Triacylglycerol lipases are well characterized enzymes that catalyze the hydrolysis of fats. They are biotechnologically relevant enzymes and are used in a wide range of practical applications in industry. Lipase produced from Burkholderia ubonensis (strain PL266-QLM) (Lipase QLM) is being investigated for use as a processing aid in multiple food applications and may therefore be present at trace levels in finished food products. A battery of toxicological studies was therefore conducted on Lipase QLM to support its safe use in food. Lipase QLM was not genotoxic or mutagenic in an in vitro bacterial reverse mutation test and chromosome aberration test. Additionally, no test article-related adverse effects were observed in clinical observations, body weight, food consumption, ophthalmology, hematology, blood chemistry, urinalysis, and macroscopic and microscopic findings in a subchronic toxicity study in rats administered Lipase QLM in the diet at levels of 0%, 0.8%, 2%, and 5% Lipase QLM. The no-observed-adverse-effect level was therefore considered to be 5% Lipase QLM in both sexes [3357.2 and 3777.6 mg/kg body weight/day (2756.3 and 3101.4 mg total organic solids/kg body weight/day) in males and females, respectively] under the test conditions, which supports the safety of this ingredient for use in food for human consumption.


Sujet(s)
Burkholderia/enzymologie , Triacylglycerol lipase/toxicité , Animaux , Lignée cellulaire , Cricetulus , Escherichia coli/effets des médicaments et des substances chimiques , Escherichia coli/génétique , Femelle , Sécurité des aliments , Mâle , Tests de mutagénicité , Dose sans effet nocif observé , Rat Sprague-Dawley , Salmonella typhimurium/effets des médicaments et des substances chimiques , Salmonella typhimurium/génétique , Tests de toxicité subchronique
8.
Case Rep Infect Dis ; 2019: 5731969, 2019.
Article de Anglais | MEDLINE | ID: mdl-31781432

RÉSUMÉ

Herpes simplex virus 1 infection is a common cause of encephalitis (HSVE) in the United States. Post-HSVE development of N-methyl-D-aspartate receptor (NMDAR) antibodies resulting in autoimmune encephalitis is a rare complication, primarily affecting children and young adults. Anti-NMDAR develops 1-4 weeks after HSVE, manifesting as choreoathetosis and/or orofacial dyskinesia in children and psychiatric symptoms in young adults. We describe a case of a 61-year-old male who presented with agitation, behavioral changes, and confusion eight months after being treated for HSVE. Extensive investigation was unrevealing except for cerebrospinal fluid lymphocytic pleocytosis, a positive anti-NMDAR Ab titer 1 : 64, and imaging changes consistent with postviral encephalitis suggestive of HSV-induced anti-NMDAR encephalitis. Aggressive therapy resulted in limited success and persistent neurologic deficits. The unique features of this case are the old age of the patient and preceding HSVE which triggered this autoimmune process. Physicians should consider anti-NMDAR encephalitis in the differentials for relapsing patients after HSVE.

9.
Nutr Rev ; 76(8): 581-602, 2018 08 01.
Article de Anglais | MEDLINE | ID: mdl-29917092

RÉSUMÉ

Context: Treatment options for nonalcoholic fatty liver disease (NAFLD) are needed. Objective: The aim of this review was to systematically assess the effects of omega-3 long-chain polyunsaturated fatty acids (n-3 LC-PUFAs), particularly eicosapentaenoic acid and docosahexaenoic acid, on liver-related and metabolic outcomes in adult and pediatric patients with NAFLD. Data Sources: The online information service ProQuest Dialog was used to search 8 literature databases. Study Selection: Controlled intervention studies in which the independent effects of n-3 LC-PUFAs could be isolated were eligible for inclusion. Data Extraction: The 18 unique studies that met the criteria for inclusion were divided into 2 sets, and data transcriptions and study quality assessments were conducted in duplicate. Each effect size was expressed as the weighted mean difference and 95%CI, using a random-effects model and the inverse of the variance as a weighting factor. Results: Based on the meta-analyses, supplementation with n-3 LC-PUFAs resulted in statistically significant improvements in 6 of 13 metabolic risk factors, in levels of 2 of 3 liver enzymes, in liver fat content (assessed via magnetic resonance imaging/spectroscopy), and in steatosis score (assessed via ultrasonography). Histological measures of disease [which were assessed only in patients with nonalcoholic steatohepatitis (NASH)] were unaffected by n-3 LC-PUFA supplementation. Conclusions: Omega-3 LC-PUFAs are useful in the dietary management of patients with NAFLD. Additional trials are needed to better understand the effects of n-3 LC-PUFAs on histological outcomes in patients with NASH. Systematic Review Registration: PROSPERO CRD42017055951.


Sujet(s)
Matières grasses alimentaires/administration et posologie , Compléments alimentaires , Acides gras omega-3/administration et posologie , Stéatose hépatique non alcoolique/thérapie , Adulte , Essais cliniques comme sujet , Acide docosahexaénoïque/administration et posologie , Acide eicosapentanoïque/administration et posologie , Femelle , Humains , Foie/métabolisme , Mâle , Adulte d'âge moyen , Stéatose hépatique non alcoolique/métabolisme , Résultat thérapeutique
10.
Article de Anglais | MEDLINE | ID: mdl-29198783

RÉSUMÉ

Cutaneous infections and infestations are common among children and adolescents. Ectoparasitic infestations affect individuals across the globe. Head lice, body lice, scabies, and infestations with bed bugs are seen in individuals who reside in both resource poor areas and in developed countries. Superficial cutaneous and mucosal candida infections occur throughout the life cycle. Dermatophyte infections of keratin-containing skin and skin structures result in tinea capitis (scalp), tinea corporis (body), tinea pedis (foot), and tinea unguium (nails). Less frequent endemic fungal infections such as blastomycosis, coccidiodomycosis, and histoplasmosis may present with skin findings. This article will describe the epidemiology and transmission of these conditions as well as their clinical manifestations. The approach to diagnosis will be addressed as well as primary prevention and current therapies.


Sujet(s)
Mycoses cutanées/diagnostic , Dermatoses parasitaires/diagnostic , Adolescent , Animaux , Punaises des lits , Candidose/diagnostic , Candidose/épidémiologie , Candidose/thérapie , Candidose cutanée/diagnostic , Candidose cutanée/épidémiologie , Candidose cutanée/thérapie , Enfant , Mycoses cutanées/épidémiologie , Mycoses cutanées/thérapie , Humains , Pédiculoses/diagnostic , Pédiculoses/épidémiologie , Pédiculoses/thérapie , Onychomycose/diagnostic , Onychomycose/épidémiologie , Onychomycose/thérapie , Pediculus , Gale/diagnostic , Gale/épidémiologie , Gale/thérapie , Dermatoses du cuir chevelu/diagnostic , Dermatoses du cuir chevelu/épidémiologie , Dermatoses du cuir chevelu/parasitologie , Dermatoses du cuir chevelu/thérapie , Peau/microbiologie , Peau/parasitologie , Peau/anatomopathologie , Dermatoses parasitaires/épidémiologie , Dermatoses parasitaires/thérapie , Teigne/diagnostic , Teigne/épidémiologie , Teigne/thérapie , Teigne tondante/diagnostic , Teigne tondante/épidémiologie , Teigne tondante/thérapie , Pied d'athlète/diagnostic , Pied d'athlète/épidémiologie , Pied d'athlète/thérapie
11.
Regul Toxicol Pharmacol ; 83: 54-65, 2017 Feb.
Article de Anglais | MEDLINE | ID: mdl-27825987

RÉSUMÉ

Bacillus subtilis CU1 is a recently described probiotic strain with beneficial effects on immune health in elderly subjects. The following work describes a series of studies supporting the safety of the strain for use as an ingredient in food and supplement preparations. Using a combination of 16S rDNA and gyrB nucleotide analyses, the species was identified as a member of the Bacillus subtilis complex (B. subtilis subsp. spizizenii). Further characterization of the organism at the strain level was achieved using random amplified polymorphic DNA polymerase chain reaction (RAPD PCR) and pulsed field gel electrophoresis (PFGE) analyses. B. subtilis CU1 did not demonstrate antibiotic resistance greater than existing regulatory cutoffs against clinically important antibiotics, did not induce hemolysis or produce surfactant factors, and was absent of toxigenic activity in vitro. Use of B. subtilis CU1 as a probiotic has recently been evaluated in a 16-week randomized, double-blind, placebo-controlled, parallel-arm study, in which 2 × 109 spores per day of B. subtilis CU1 were administered for a total 40 days to healthy elderly subjects (4 consumption periods of 10 days separated by 18-day washouts). This work describes safety related endpoints not previously reported. B. subtilis CU1 was safe and well-tolerated in the clinical subjects without undesirable physiological effects on markers of liver and kidney function, complete blood counts, hemodynamic parameters, and vital signs.


Sujet(s)
Bacillus subtilis/physiologie , Sécurité des aliments , Probiotiques/toxicité , Sujet âgé , Antibactériens/pharmacologie , Bacillus subtilis/effets des médicaments et des substances chimiques , Bacillus subtilis/génétique , Bacillus subtilis/pathogénicité , Sécurité des produits de consommation , Profilage d'ADN , DNA gyrase/génétique , ADN bactérien/génétique , Méthode en double aveugle , Résistance bactérienne aux médicaments , Électrophorèse en champ pulsé , Femelle , Hémolyse , Humains , Mâle , Tests de sensibilité microbienne , Adulte d'âge moyen , Réaction de polymérisation en chaîne , ARN ribosomique 16S/génétique , Ribotypage , Appréciation des risques , Facteurs temps
12.
Regul Toxicol Pharmacol ; 80: 71-81, 2016 Oct.
Article de Anglais | MEDLINE | ID: mdl-27311684

RÉSUMÉ

Euglena gracilis is a microalga capable of synthesizing various nutrients of interest in human and animal nutrition. When cultivated aerobically in the dark, Euglena synthesize paramylon, a storage polysaccharide comprised of high molecular weight beta-1,3-D-glucose polymers organized in cytoplasmic granules. Beta-glucans have been shown to have immune modulation effects, including anti-microbial, anti-tumor, and anti-oxidant properties, and metabolic effects, such as regulation of cholesterol and blood sugar levels. Preparations of E. gracilis and paramylon may therefore have potential utility as functional food ingredients for human and animal nutrition. A battery of toxicological studies was conducted on a dried preparation of E. gracilis and paramylon to support their safe food use. The dried alga was not genotoxic in a bacterial reverse mutation test and mammalian micronucleus test. In the subchronic toxicity study, rats were provided E. gracilis in the diet at levels of 0, 12,500, 25,000 or 50,000 ppm. Paramylon was provided at a concentration of 50,000 ppm. No effects that could be attributable to treatment were observed in clinical observations, body weight, food consumption, ophthalmology, hematology and clinical chemistry, urinalysis, and macroscopic and microscopic findings. A NOAEL of 50,000 ppm in the diet was determined for both ingredients.


Sujet(s)
Euglena gracilis/métabolisme , Sécurité des aliments , Aliment fonctionnel/toxicité , Glucanes/toxicité , Tests de mutagénicité/méthodes , Tests de toxicité subchronique/méthodes , Administration par voie orale , Animaux , ADN bactérien/effets des médicaments et des substances chimiques , ADN bactérien/génétique , Dessiccation , Relation dose-effet des médicaments , Femelle , Glucanes/administration et posologie , Glucanes/métabolisme , Humains , Mâle , Micronoyaux à chromosomes défectueux/induit chimiquement , Tests de micronucleus , Mutagenèse , Dose sans effet nocif observé , Poudres , Rat Sprague-Dawley , Appréciation des risques , Facteurs temps
13.
Article de Anglais | MEDLINE | ID: mdl-25703483

RÉSUMÉ

Infections caused by viruses are universal during childhood and adolescence. Clinicians will regularly care for children and adolescents who present with infections caused by a wide number of viral pathogens. These infections have varied presentations. Many infections may have clinical presentations that are specific to the infecting virus but present differently, based on the age and immunocompetence of the patient. Some children are directly impacted early in their lives when maternal disease results in an in utero infection (cytomegalovirus, rubella virus, or parvovirus B19). Other viruses may infect children in a predictable pattern as they grow older (rhinovirus or influenza virus). Fortunately, many viral infections frequently encountered in the past are no longer extant due to widespread immunization efforts. Recognition of these vaccine-preventable infections is important because outbreaks of some of these diseases (mumps or measles) continue to occur in the United States. Vigilance in vaccine programs against these viral agents can prevent their re-emergence. In addition, an increasing number of viral infections (herpes simplex virus, influenza virus, varicella zoster virus, or cytomegalovirus) can now be successfully treated with antiviral medications. Most viral infections in children result in self-limited illness and are treated symptomatically and infected children experience full recovery. This review will address the epidemiology, clinical presentation, diagnosis, treatment, and prevention of viral infections commonly encountered by the clinician.


Sujet(s)
Maladies virales/épidémiologie , Antiviraux/usage thérapeutique , Enfant , Humains , Vaccins antiviraux , Maladies virales/diagnostic , Maladies virales/traitement médicamenteux , Maladies virales/prévention et contrôle
14.
Regul Toxicol Pharmacol ; 69(1): 1-6, 2014 Jun.
Article de Anglais | MEDLINE | ID: mdl-24569051

RÉSUMÉ

Amizate® is a proprietary protein hydrolysate preparation derived from Atlantic salmon (Salmo salar) using endogenous hydrolytic enzymes; it contains mostly free amino acids and short peptides, as well as small amounts of micronutrients (i.e., vitamins and minerals). In this study, the safety of supplementation with fish protein hydrolysate (Amizate®) was examined in 438 malnourished children in a randomized, placebo-controlled, double-blind, and parallel study. The children were between the ages of six to eight and met the Gomez classification for mild or moderate malnutrition. They were randomized to receive one of three interventions for four months, including a chocolate drink (control), or Amizate® (3 or 6g/day) in a chocolate drink. Administration of Amizate® was well-tolerated, with no adverse events reported. Growth (i.e., body weight gain, changes in height, and body mass index) was not negatively impacted by administration of Amizate®, and routine biochemical analysis of blood and urine samples did not reveal any abnormalities that were attributable to the intervention. Findings from this study demonstrate that daily consumption of 3 or 6g of fish protein hydrolysate (Amizate®) was safe and suitable for supplementing the diets of malnourished children.


Sujet(s)
Troubles nutritionnels de l'enfant/diétothérapie , Compléments alimentaires/effets indésirables , Produits de la pêche/effets indésirables , Protéines de poisson/effets indésirables , Hydrolysats de protéines/administration et posologie , Hydrolysats de protéines/effets indésirables , Animaux , Enfant , Régime alimentaire/effets indésirables , Méthode en double aveugle , Femelle , Protéines de poisson/administration et posologie , Humains , Mâle
15.
PLoS One ; 7(8): e40702, 2012.
Article de Anglais | MEDLINE | ID: mdl-22870201

RÉSUMÉ

An unknown vitamin D compound was observed in the HPLC-UV chromatogram of edible mushrooms in the course of analyzing vitamin D(2) as part of a food composition study and confirmed by liquid chromatography-mass spectrometry to be vitamin D(4) (22-dihydroergocalciferol). Vitamin D(4) was quantified by HPLC with UV detection, with vitamin [(3)H] itamin D(3) as an internal standard. White button, crimini, portabella, enoki, shiitake, maitake, oyster, morel, chanterelle, and UV-treated portabella mushrooms were analyzed, as four composites each of a total of 71 samples from U.S. retail suppliers and producers. Vitamin D(4) was present (>0.1 µg/100 g) in a total of 18 composites and in at least one composite of each mushroom type except white button. The level was highest in samples with known UV exposure: vitamin D enhanced portabella, and maitake mushrooms from one supplier (0.2-7.0 and 22.5-35.4 µg/100 g, respectively). Other mushrooms had detectable vitamin D(4) in some but not all samples. In one composite of oyster mushrooms the vitamin D(4) content was more than twice that of D(2) (6.29 vs. 2.59 µg/100 g). Vitamin D(4) exceeded 2 µg/100 g in the morel and chanterelle mushroom samples that contained D(4), but was undetectable in two morel samples. The vitamin D(4) precursor 22,23-dihydroergosterol was found in all composites (4.49-16.5 mg/100 g). Vitamin D(4) should be expected to occur in mushrooms exposed to UV light, such as commercially produced vitamin D enhanced products, wild grown mushrooms or other mushrooms receiving incidental exposure. Because vitamin D(4) coeluted with D(3) in the routine HPLC analysis of vitamin D(2) and an alternate mobile phase was necessary for resolution, researchers analyzing vitamin D(2) in mushrooms and using D(3) as an internal standard should verify that the system will resolve vitamins D(3) and D(4).


Sujet(s)
Agaricales/composition chimique , Analyse d'aliment , Vitamine D/analyse , Agaricales/métabolisme , Chromatographie en phase liquide à haute performance/instrumentation , Chromatographie en phase liquide à haute performance/méthodes , Spectrométrie de masse/méthodes , Rayons ultraviolets , Vitamine D/métabolisme
16.
Regul Toxicol Pharmacol ; 63(2): 313-20, 2012 Jul.
Article de Anglais | MEDLINE | ID: mdl-22561556

RÉSUMÉ

A significant number of human clinical trials have reported no adverse effects associated with consumption of Lactobacillus reuteri (L. reuteri). In the present study, the clinical safety and toxicology of oral ingestion of supplement capsules containing L. reuteri NCIMB 30242 was investigated. A randomized group of 131 subjects received a dose of 2.9×109 CFU L. reuteri NCIMB 30242 capsules (n=67) or placebo capsules (n=64) twice daily for 9 weeks. Clinical chemistry and hematological parameters of safety were analyzed. The frequency, duration and intensity of adverse events (AE)s and clinical significance of safety parameters were recorded for both groups. No clinically significant differences between the probiotic capsule and placebo capsule treated groups were detected in either the blood clinical chemistry or hematology results. The frequency and intensity of AEs was similar in the two groups. These results demonstrate that administration of a twice daily dose of 2.9×109 CFU was safe and well tolerated in the population evaluated over 9 weeks.


Sujet(s)
Sécurité des produits de consommation , Limosilactobacillus reuteri , Probiotiques/effets indésirables , Adulte , Sujet âgé , Capsules , Cholestérol LDL/sang , Méthode en double aveugle , Femelle , Humains , Hypercholestérolémie/sang , Hypercholestérolémie/traitement médicamenteux , Mâle , Adulte d'âge moyen , Probiotiques/administration et posologie , Probiotiques/usage thérapeutique , Résultat thérapeutique , Jeune adulte
17.
Regul Toxicol Pharmacol ; 61(2): 215-21, 2011 Nov.
Article de Anglais | MEDLINE | ID: mdl-21821088

RÉSUMÉ

Aloesin is a chromone that is a component of Aloe spp. It may have potential as a functional food ingredient as it has been shown to likely have beneficial effects in persons in a pre-diabetic state or who have metabolic syndrome. In this study the safety of aloesin has been evaluated using a series of in vitro and in vivo genotoxicity assays including, bacterial mutation, mammalian cell cytogenetic, and mouse micronucleus tests. Aloesin did not induce reverse mutations in Salmonella typhimurium and Escherichia coli at any of the tested dose levels up to 10,000 µg/plate. Similarly, aloesin did not increase the incidence of chromosome aberrations when incubated with Chinese hamster lung cells at any of the tested concentrations up to 10,000 µg/mL. In vivo, there was no effect of aloesin on the incidence of micronucleated erythrocytes following oral administration on two consecutive days at doses up to 5000 mg/kg body weight. There was no evidence of toxicity to bone marrow. The results of these studies demonstrate that aloesin is without genotoxic potential.


Sujet(s)
4H-1-Benzopyran-4-ones/toxicité , Aberrations des chromosomes/induit chimiquement , Glucosides/toxicité , Mutagènes/toxicité , Animaux , Moelle osseuse/effets des médicaments et des substances chimiques , Lignée cellulaire , Cricetinae , Cricetulus , Érythrocytes/effets des médicaments et des substances chimiques , Escherichia coli/effets des médicaments et des substances chimiques , Femelle , Mâle , Souris , Souris de lignée ICR , Tests de micronucleus/méthodes , Tests de mutagénicité/méthodes , Rats , Rat Sprague-Dawley , Salmonella typhimurium/effets des médicaments et des substances chimiques
18.
J Agric Food Chem ; 59(16): 8724-32, 2011 Aug 24.
Article de Anglais | MEDLINE | ID: mdl-21736377

RÉSUMÉ

This study compared the compositional changes in mushrooms exposed to sunlight with those occurring after commercial ultraviolet (UV) light processing. Button mushrooms (75 kg) were processed in the presence or absence of UVB light; a third group was exposed to direct sunlight. Mushroom composition was evaluated using chemical analyses. Vitamin D concentrations were 5, 410, and 374 µg/100 g (dw) in control, UVB, and sunlight groups, respectively. On a dry weight basis, no significant changes in vitamin C, folate, vitamins B(6), vitamin B(5), riboflavin, niacin, amino acids, fatty acids, ergosterol, or agaritine were observed following UVB processing. Sunlight exposure resulted in a 26% loss of riboflavin, evidence of folate oxidation, and unexplained increases in ergosterol (9.5%). It was concluded that compositional effects of UVB light are limited to changes in vitamin D and show no detrimental changes relative to natural sunlight exposure and, therefore, provide important information relevant to the suitability and safety of UVB light technology for vitamin D enhanced mushrooms.


Sujet(s)
Agaricus/composition chimique , Agaricus/effets des radiations , Lumière du soleil , Rayons ultraviolets , Vitamine D/analyse , Acides aminés/analyse , Acides gras/analyse , Phénylhydrazines/analyse
19.
Regul Toxicol Pharmacol ; 61(2): 161-71, 2011 Nov.
Article de Anglais | MEDLINE | ID: mdl-21784118

RÉSUMÉ

Aloesin, an aromatic chromone present in various Aloe species, shows potential beneficial effects on indices related to pre-diabetic states, including metabolic syndrome. Aloesin may have utility as a functional food ingredient. As part of a program to assess its safety, aloesin was administered by oral gavage at doses of 250, 500, and 1000 mg/kg body weight/day to groups of 10 male and 10 female Sprague-Dawley rats for 90 days. Treatment was not associated with mortality and appeared to be well tolerated. There were no toxicologically or statistically significant changes in body weight gain or in feed and water consumption. A few statistically significant changes in serum biochemistry and hematology parameters were noted, but all were mild in nature, were confined to one sex, and/or did not show dose-response relationships. Urinalysis revealed dose-dependent increases in urinary ketones. This result was due to the presence of aloesin, which possesses ketone functionalities, in the urine and not due to a systemic effect. There was no effect of treatment on organ weights or on the results of the histopathological examinations. The no-observed-adverse-effect level was considered to be 1000 mg/kg body weight/day, the highest dose tested. The results support potential use of aloesin as a functional food ingredient.


Sujet(s)
4H-1-Benzopyran-4-ones/toxicité , Glucosides/toxicité , Administration par voie orale , Animaux , Poids/effets des médicaments et des substances chimiques , 4H-1-Benzopyran-4-ones/administration et posologie , Relation dose-effet des médicaments , Consommation de boisson/effets des médicaments et des substances chimiques , Consommation alimentaire/effets des médicaments et des substances chimiques , Oeil/effets des médicaments et des substances chimiques , Femelle , Glucosides/administration et posologie , Cétones/urine , Mâle , Dose sans effet nocif observé , Taille d'organe/effets des médicaments et des substances chimiques , Rats , Rat Sprague-Dawley , Prise de poids/effets des médicaments et des substances chimiques
20.
J Agric Food Chem ; 59(14): 7841-53, 2011 Jul 27.
Article de Anglais | MEDLINE | ID: mdl-21663327

RÉSUMÉ

Vitamin D(2) (ergocalciferol) and sterols were analyzed in mushrooms sampled nationwide in the United States to update the USDA Nutrient Database for Standard Reference. Vitamin D(2) was assayed using HPLC with [(3)H]-vitamin D(3) internal standard and sterols by GC-FID mass spectrometric (MS) confirmation. Vitamin D(2) was low (0.1-0.3 µg/100 g) in Agaricus bisporus (white button, crimini, portabella) and enoki, moderate in shiitake and oyster (0.4-0.7 µg/100 g), and high in morel, chanterelle, maitake (5.2-28.1 µg/100 g) and UV-treated portabella (3.4-20.9 µg/100 g), with significant variability among composites for some types. Ergosterol (mg/100 g) was highest in maitake and shiitake (79.2, 84.9) and lowest in morel and enoki (26.3, 35.5); the range was <10 mg/100 g among white button composites but 12-50 mg/100 g among samples of other types. All mushrooms contained ergosta-5,7-dienol (22,23-dihydroergosterol) (3.53-18.0 mg/100 g) and (except morel) ergosta-7-enol. Only morel contained brassicasterol (28.6 mg/100 g) and campesterol (1.23-4.54 mg/100 g) and no ergosta-7,22-dienol. MS was critical in distinguishing campesterol from ergosta-7,22-dienol.


Sujet(s)
Agaricales/composition chimique , Ergocalciférol/analyse , Stérols/analyse , États-Unis
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...